Most cases of bacterial vaginosis clear up within about seven days of starting antibiotic treatment, with symptoms often fading in the first few days. Short-term cure rates for standard therapy sit around 80 to 87 percent, depending on the specific regimen. But that headline number hides a frustrating reality: BV comes back for a large share of women within months, and what “going away” truly means depends on whether you are asking about symptom relief, lab results, or the deeper shifts happening in your vaginal microbiome.
What Standard Treatment Looks Like
The most widely prescribed treatment is a seven-day course of oral metronidazole, typically taken twice a day. Alternatively, your provider may prescribe metronidazole vaginal gel or clindamycin cream applied for five to seven days. A meta-analysis comparing different metronidazole regimens found that cure rates on the initial follow-up visit were broadly similar regardless of whether patients received a single large dose, a two-day course, a five-day course, or the full seven days, with cure rates ranging from 85 to 87 percent across groups.1JAMA. Comparison of Different Metronidazole Therapeutic Regimens for Bacterial Vaginosis: A Meta-analysis Thirty-day cure rates for the standard seven-day oral course hover around 80 percent.2PubMed Central. Understanding and Preventing Recurring Bacterial Vaginosis: Important Considerations for Clinicians
Many women notice a difference within the first few days. In qualitative interviews, some described symptoms starting to fade around day four of oral antibiotics.3PLOS ONE. Acceptability of and treatment preferences for recurrent bacterial vaginosis—Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial The characteristic fishy odor and discharge typically improve before the course is finished, though providers generally recommend completing the full prescription. The clinical “test of cure” visit is usually scheduled about one to two weeks after treatment ends, which is when a provider confirms that the infection has resolved based on examination and lab criteria.
How Your Microbiome Recovers
Symptom relief and actual microbiome recovery are not the same thing. You can feel better within days while the bacterial community in your vagina is still reshuffling. An observational study that tracked vaginal bacteria before and after metronidazole treatment found that by day eight, the microbiome of treated women was dominated by one particular species of Lactobacillus, at levels significantly higher than those in healthy controls. It was not until around day fifteen that the overall bacterial profile of treated women actually resembled that of women who never had BV.4PubMed Central. Recovery of Vaginal Microbiota after Standard Treatment for Bacterial Vaginosis Infection: An Observational Study
This matters because the speed of microbiome recovery can affect whether BV stays gone. The vaginal environment needs to re-establish a healthy balance of acid-producing bacteria that keep problematic organisms in check. If that process is interrupted or incomplete, the conditions that favor BV can reassert themselves quickly.
Why BV Comes Back So Often
Recurrence is the defining challenge of BV. In a study that followed 117 women for a full year after oral metronidazole treatment, about 58 percent had a recurrence of BV, and roughly 69 percent had abnormal vaginal flora return by the twelve-month mark.5PubMed. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence Those numbers are striking: the majority of women who clear BV with a standard course end up dealing with it again within a year.
One major reason is biofilms. The bacteria involved in BV, particularly Gardnerella vaginalis, can form a sticky, structured community on the vaginal lining. This biofilm acts as a physical shield. Antibiotics that circulate freely in vaginal fluid may not penetrate the biofilm well enough to kill the bacteria hiding inside it.6PubMed Central. Fighting polymicrobial biofilms in bacterial vaginosis Bacteria embedded in a biofilm can also slow their growth to a near-dormant state, making them even less vulnerable to antibiotics, which generally work best against actively dividing cells.7Indian Journal of Dermatology, Venereology and Leprology. Bacterial vaginosis and biofilms: Therapeutic challenges and innovations – A narrative review This is not unique to BV; biofilms play a similar role in chronic wound infections, dental plaque, and other persistent bacterial problems. But it helps explain why a treatment course that clears symptoms and even normalizes a lab test can still leave enough bacteria in place to trigger a relapse weeks later.8PubMed. Etiology of bacterial vaginosis and polymicrobial biofilm formation
Single-Dose and Shorter Treatment Options
Because a full seven-day course is inconvenient and comes with side effects like nausea and a metallic taste, there has been interest in shorter regimens. A newer option is secnidazole, a drug related to metronidazole that can be taken as a single oral dose of two grams. In a head-to-head trial, a single dose of secnidazole produced a cure rate of about 60 percent at the follow-up visit, which was statistically equivalent to a multi-day course of metronidazole.9PubMed Central. Treatment of bacterial vaginosis: a multicenter, double-blind, double-dummy, randomised phase III study comparing secnidazole and metronidazole A separate study reported a four-week cure rate of about 80 percent for secnidazole given as a single dose.10PubMed Central. A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis A systematic review pooling multiple trials confirmed no significant difference in cure rates between single-dose secnidazole and standard multi-day metronidazole.11PubMed Central. Secnidazole for treatment of bacterial vaginosis: a systematic review
The convenience is obvious: one dose, taken once, often mixed into yogurt or applesauce. But single-dose treatments share the same recurrence problem as longer courses. The biofilm is not more vulnerable just because the drug was delivered faster.
Maintenance Therapy for Recurrent BV
If BV keeps returning, the treatment timeline shifts from days to months. Guidelines for recurrent BV typically recommend an initial extended course of metronidazole, taken for ten to fourteen days, followed by a long maintenance phase using metronidazole vaginal gel twice a week for three to six months.12PubMed. Characterization and Treatment of Recurrent Bacterial Vaginosis
This approach works better than one-and-done treatment, but the numbers are sobering. In a randomized trial of twice-weekly metronidazole gel used as suppressive therapy, only about 26 percent of women in the treatment group had a recurrence during the active suppression period, compared with 59 percent in the placebo group. But once suppressive treatment stopped, recurrence climbed: by 28 weeks of total follow-up, about half of the treated group had relapsed.13PubMed. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis Another study found that among women who were compliant with maintenance gel, roughly 70 percent remained free of symptomatic BV at six months, and that rate held at twelve months for those who made it to the six-month observation point.14PubMed Central. Recurrent Bacterial Vaginosis: An Unmet Therapeutic Challenge One important side effect of prolonged antibiotic use is vaginal yeast infections, which are common enough during suppressive therapy that some providers prescribe antifungal medication alongside it.
Probiotics as Add-On or Alternative
Because antibiotics alone clearly have limits, there is growing interest in probiotics, either alongside or following standard treatment. The logic is straightforward: if BV is a disruption of the vaginal bacterial community, introducing beneficial bacteria might help restore and maintain the right balance.
A systematic review identified Lactobacillus rhamnosus as one of the most effective strains, finding it significantly improved vaginal pH and microbiome composition and reduced recurrence.15PubMed Central. Effective probiotic regimens for bacterial vaginosis treatment and recurrence prevention: A systematic review In a double-blind trial involving over 500 women, about 62 percent of those receiving oral probiotic capsules had restored vaginal microbiota after treatment, compared with about 27 percent in the placebo group, a gap that remained significant at a six-week follow-up.16PubMed. Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study A trial in Chinese women with asymptomatic BV found that while initial cure rates were similar between probiotics and metronidazole, recurrence rates over the following months were dramatically lower in the probiotic group.17Scientific Reports. Probiotics reduce the recurrence of asymptomatic bacterial vaginosis in Chinese women
Probiotics are not a universal fix, and the evidence is still catching up to the enthusiasm. Different strains and doses produce different results, and what works in one clinical trial may not be available over the counter in the same formulation. But the pattern across studies is encouraging, especially for reducing how often BV comes back.
Does Treating a Male Partner Help?
BV is not considered a sexually transmitted infection in the traditional sense, but sexual activity clearly plays a role in its development and recurrence. This has led to an obvious question: if a woman keeps getting BV, should her male sexual partner be treated too?
A 2025 trial from Australia grabbed headlines when it found that treating male partners with a combination of oral antibiotics and a topical penile antibiotic cut BV recurrence roughly in half. In that trial, recurrence occurred in 35 percent of women whose partners were treated, compared with 63 percent in the control group.18PubMed. Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis The result was exciting because nothing else has come close to that level of recurrence reduction.
But context matters. A subsequent meta-analysis pooling multiple trials, including the Australian one, found no overall significant benefit from treating male partners. When the Australian trial was excluded from the analysis, the effect essentially disappeared, and the authors concluded that male partner monotherapy alone is unlikely to reduce BV recurrence.19PubMed. The efficacy of male partner treatment to prevent recurrence of bacterial Vaginosis: A systematic review with Meta-Analysis of randomized controlled trials The difference may hinge on the specific approach: the Australian trial was the only one that combined both oral and topical treatment for the male partner. This suggests that if concurrent partner treatment is going to work, it probably needs to be more aggressive than a single prescription. The science is genuinely unsettled on this, and clinical guidelines in most countries do not yet recommend routine male partner treatment.
Habits and Contraception That Affect Your Timeline
Certain everyday factors can make BV harder to clear or more likely to return. Vaginal douching is the best-documented one. A longitudinal study found that regular douching increased the risk of BV by about 21 percent compared with not douching at all.20PubMed Central. A Longitudinal Study of Vaginal Douching and Bacterial Vaginosis—A Marginal Structural Modeling Analysis Women who had douched within the previous seven days were at roughly double the odds of having BV.21PubMed. Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina The mechanism is straightforward: douching washes away the protective lactobacilli that keep the vaginal pH low, opening the door for BV-associated bacteria to take over.
Contraceptive choice is another underappreciated factor. The copper intrauterine device (IUD) has been linked to higher BV risk in multiple studies. A prospective cohort study found that copper IUD users had about 1.3 times the risk of BV compared with women using no contraception or other nonhormonal methods, and the risk was highest in the first six months after insertion.22PubMed Central. Elevated Risk of Bacterial Vaginosis Among Users of the Copper Intrauterine Device: A Prospective Longitudinal Cohort Study A randomized trial comparing contraceptive methods confirmed that women assigned to the copper IUD had significantly higher Nugent scores, the lab measure used to grade BV, after six months compared with women using hormonal methods.23PubMed Central. Contraceptive effects on the cervicovaginal microbiome: Recent evidence including randomized trials If you are dealing with stubborn recurrent BV and have a copper IUD, it is worth discussing this with your provider. Among women who discontinued the copper IUD in the cohort study, BV rates returned to pre-insertion levels within a year.22PubMed Central. Elevated Risk of Bacterial Vaginosis Among Users of the Copper Intrauterine Device: A Prospective Longitudinal Cohort Study
What Happens If You Leave BV Untreated
Some women with mild or asymptomatic BV wonder whether they even need treatment. BV can occasionally resolve on its own, but leaving it untreated carries real risks, especially during pregnancy. A study of pregnant women with BV found a significantly higher rate of preterm birth before 34 weeks compared with women without BV, along with higher rates of neonatal intensive care admission and respiratory distress in the newborns.24PubMed Central. Maternal and fetal outcomes of pregnant women with bacterial vaginosis A Cochrane review confirmed that antibiotic treatment is highly effective at clearing BV during pregnancy and found that treating it may reduce the incidence of delivery before 37 weeks, with the strongest protective effect in women who had a prior preterm birth.25Cochrane Library. Antibiotics for treating bacterial vaginosis in pregnancy
Outside of pregnancy, untreated BV has been associated with increased susceptibility to sexually transmitted infections, including chlamydia, gonorrhea, and HIV, as well as a higher risk of pelvic inflammatory disease and infertility.26American Journal of Obstetrics & Gynecology. Bacterial vaginosis and association with infertility, endometritis, and pelvic inflammatory disease The disrupted vaginal environment in BV reduces the acidic barrier that normally helps block pathogens, which is why the infection matters even when symptoms are tolerable.
Boric Acid and Other Vaginal Acidifiers
Boric acid vaginal suppositories have gained popularity as an over-the-counter option, especially among women frustrated with antibiotic cycles. These work by lowering vaginal pH, creating an environment less hospitable to BV-associated bacteria. A recent study of intravaginal boric acid for recurrent BV found that vaginal pH normalized in about 87 percent of participants, the most consistent improvement observed among all the vaginal health measures tracked.27PubMed Central. Intravaginal boric acid treatment for recurrent bacterial vaginosis: short-term effects on vaginal health parameters and patient satisfaction That is promising for short-term symptom management and as a bridge strategy, but boric acid is not a substitute for antibiotics when a confirmed infection needs clearing. It is also toxic if swallowed, so it must only be used vaginally and kept away from children.
Lactic acid gels work on a similar principle. Women in a qualitative study described lactic acid gel as fast-acting, giving instant relief, but the majority recalled that BV symptoms returned within one to two weeks of completing treatment.3PLOS ONE. Acceptability of and treatment preferences for recurrent bacterial vaginosis—Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial Acidifying agents may be useful as part of a maintenance routine, especially between antibiotic courses, but on their own they do not tackle the biofilm problem that drives recurrence.
Why the “How Long” Question Does Not Have One Answer
The honest answer to how long BV takes to go away depends entirely on which version of “go away” you mean. If you mean symptom relief, expect a few days on antibiotics. If you mean a clean test result, about one to two weeks after completing treatment. If you mean your vaginal microbiome returning to a healthy profile, roughly two weeks, based on the limited data available. And if you mean staying gone, the evidence is less reassuring: without a maintenance strategy, the odds of recurrence within a year are better than even.
For a first episode, a single standard course of treatment resolves the infection for most women and the whole thing is over within a couple of weeks. For women dealing with their second or third recurrence, the timeline stretches into months of suppressive therapy, with probiotics, lifestyle adjustments, and possibly partner treatment layered on top. The gap between those two experiences is enormous, and it is one reason BV generates so much frustration in online forums and clinical waiting rooms alike. The condition is easy to treat in the short term and genuinely difficult to keep away in the long term, and there is no single intervention that reliably solves the recurrence puzzle for everyone.